How much funding has CryptoMedix raised?

CryptoMedix has disclosed $276.5K raised across 1 round.

Where is CryptoMedix headquartered?

CryptoMedix is headquartered in Harpswell, US.

CryptoMedix

Harpswell, US · Founded 2013 · Delaware corporation

CryptoMedix Inc. is a pre-clinical biotech developing first-in-class therapeutic antibodies (CMX-101 and CMX-102) targeting the tumor microenvironment for immuno-oncology, promoting cytotoxic T-cell activity and interacting with immune checkpoints such as PD(L)1 and LAG-3. Its CMX-102 antibody is also positioned for use as antibody-drug conjugates and radionuclide conjugates targeting tumor cells.

Biotech Healthtech

Founders & leadership

Janet Yancey-WronaExecutive

Bernd SeizingerExecutive

Board

Bob DavisBoard director

Leonard LiebesBoard director

Bob SuvaBoard director

Reported raises · per SEC filings

Form D private placements

$276.5K disclosed across 1 round · 2016

▶$276.5KraisedJun 2016 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Janet Yancey-WronaExecutive Officer, Director
Bob DavisDirector
Bernd SeizingerExecutive Officer, Director
Leonard LiebesDirector
Bob SuvaDirector

Offering amount: $500K
Amount sold: $276.5K
Minimum investment: $500
First sale: Jan 2016
Incorporated: Corporation, Delaware, 2013
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with CryptoMedix for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does CryptoMedix do?: CryptoMedix Inc. is a pre-clinical biotech developing first-in-class therapeutic antibodies (CMX-101 and CMX-102) targeting the tumor microenvironment for immuno-oncology, promoting cytotoxic T-cell activity and interacting with immune checkpoints such as PD(L)1 and LAG-3. Its CMX-102 antibody is also positioned for use as antibody-drug conjugates and radionuclide conjugates targeting tumor cells.
How much funding has CryptoMedix raised?: CryptoMedix has disclosed $276.5K raised across 1 round.
Where is CryptoMedix headquartered?: CryptoMedix is headquartered in Harpswell, US.